AstraZeneca and Oxford University have found a “formula for success” in developing a vaccine against the coronavirus COVID-19 that will achieve efficacy of more than 90%.
The British pharmaceutical company’s chief executive, Pascal Sorio, told The Sunday Times.
“We believe we have managed to find a formula for success and a way to reach the same high efficacy rates as everyone else after administering two doses. I can’t say any more as we have yet to release this data,” commented Sorio.
He said AstraZeneca plans to evaluate the efficacy of the drug against a new strain of coronavirus identified in the UK, which is thought to be more infectious than previously encountered.
“So far we believe the vaccine will be effective against the new strain. However, we cannot be certain of this as we are just about to test it,” Sorio added.
Note that the vaccine from US company Pfizer and partner BioNTech is estimated to be 95% effective. The Moderna drug showed 94.5%.
AstraZeneca’s antidote in the clinical trial showed only 62% in one group of volunteers, and 90% in another, smaller group that received the drug in a different dosage.